Literature DB >> 2000700

The thyroid hormone analogue SKF-94901 and iodothyronine binding sites in mammalian tissues: differences in cytoplasmic binding between liver and heart.

J W Barlow1, L E Raggatt, C F Lim, E Kolliniatis, D J Topliss, J R Stockigt.   

Abstract

The thyroid hormone analogue, SKF-94901 exhibits greater thyromimetic activity in the liver than in the heart. This difference in activity may reflect heterogeneity in the affinity of SKF-94901 for different forms of the T3 receptor. A difference in extranuclear transport of the analogue could also account for the different response of these two tissues. To distinguish between these possibilities we have examined the binding of SKF-94901 to membrane, cytosolic and nuclear preparations from liver and heart of the primate, Macaca fascicularis. Uptake of SKF-94901 into H4 liver cells was low. Binding of [125I]T3 to cell membrane preparations (Kd approximately 3 mumol/l), and to nuclear extracts (Kd approximately 0.2 nmol/l) was displaceable by SKF-94901 with a potency 2-5% that of T3 in each case. No significant difference was observed between liver and heart for SKF-94901 binding to membranes or nuclear extract. With cytosol, [125I]T3 binding was identical in heart (Kd, 22.7 +/- 10.4 nmol/l) and liver tissue (Kd, 30.3 +/- 11.1 nmol/l). In liver, and in cardiac cytosol after preliminary washing to remove serum, iodothyronine potency was in the order T3 greater than T4 greater than rT3. The ratio of SKF-94901 to T3 concentrations which gave 50% displacement was 15.9 +/- 6.8 in the liver; and 152.3 +/- 89.1 in the heart (p less than 0.05). The selective tissue activity of SKF-94901 may be related to a reduced affinity of the analogue for the cytosolic binding proteins in the heart, rather than a difference in affinity for various forms of the T3 receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2000700     DOI: 10.1530/acta.0.1240037

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  2 in total

1.  Thyroid hormone analog 3,5-diiodothyropropionic acid promotes healthy vasculature in the adult myocardium independent of thyroid effects on cardiac function.

Authors:  Yingheng Liu; Dajun Wang; Rebecca A Redetzke; Benjamin A Sherer; A Martin Gerdes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

2.  Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.

Authors:  Gary J Grover; Karin Mellström; Liu Ye; Johan Malm; Yi-Lin Li; Lars-Göran Bladh; Paul G Sleph; Mark A Smith; Rocco George; Björn Vennström; Kasim Mookhtiar; Ryan Horvath; Jessica Speelman; Donald Egan; John D Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-29       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.